•Glaukos reports positive topline phase 4 data on iDose TR in combo with cataract surgery•FDA clears Surrozen's IND for DME therapy•Empire Forum co-chairs preview retina's new investor-industry meeting•Bausch + Lomb's oral dry AMD therapy advances to clinical evaluation •Glaukos reports positive 3-year, phase 3 Epioxa clinical outcomes•Glaukos reports positive topline phase 4 data on iDose TR in combo with cataract surgery•FDA clears Surrozen's IND for DME therapy•Empire Forum co-chairs preview retina's new investor-industry meeting•Bausch + Lomb's oral dry AMD therapy advances to clinical evaluation •Glaukos reports positive 3-year, phase 3 Epioxa clinical outcomes
HEADLINES
FEATURED
Phentolamine ophthalmic solution 0.75% now has two indications in the U.S.; commercial launch timeframe is unknown as Viatris seeks a partner.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
